🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

John Paulson’s FOLD Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+32,400 Shares
Current Position
32,400 Shares
$468,504 Value

John Paulson's FOLD Position Overview

John Paulson (via Paulson & Co. Inc.) currently holds 32,400 shares of Amicus Therapeutics, Inc. (FOLD) worth $468,504, representing 0.02% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, John Paulson has initiated a new position in FOLD, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

John Paulson's Amicus Therapeutics (FOLD) Holding Value Over Time

Track share changes against reported price movement

Quarterly Amicus Therapeutics (FOLD) Trades by John Paulson

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +32,400 New Buy 32,400 $14.46

John Paulson's Amicus Therapeutics Investment FAQs

John Paulson first purchased Amicus Therapeutics, Inc. (FOLD) in Q1 2026, acquiring 32,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

John Paulson has held Amicus Therapeutics, Inc. (FOLD) for 1 quarters since Q1 2026.

John Paulson's largest addition to Amicus Therapeutics, Inc. (FOLD) was in Q1 2026, adding 32,400 shares worth $468,504.

According to the latest 13F filing for Q1 2026, John Paulson's firm, Paulson & Co. Inc., owns 32,400 shares of Amicus Therapeutics, Inc. (FOLD), valued at approximately $468,504.

As of the Q1 2026 filing, Amicus Therapeutics, Inc. (FOLD) represents approximately 0.02% of John Paulson's publicly disclosed stock portfolio, making it one of their key holdings.

John Paulson's peak holding in Amicus Therapeutics, Inc. (FOLD) was 32,400 shares, as reported at the end of Q1 2026.